JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A2251 Tivozanib (AV-951)

Target: VEGFR

Summary: VEGFR inhibitor,potent and selective

≥22.75 mg/mL
A2597 Brivanib (BMS-540215)

Target: VEGFR|FGFR|Flk1

Summary: VEGFR-2 inhibitor,ATP-competitive

insoluble in H2O; ≥18.5 mg/mL
A2174 Lenvatinib (E7080)

Target: VEGFR|PDGFR|RET

Summary: VEGFR inhibitor

≥21.35 mg/mL
A5057 MGCD-265

Target: VEGFR|c-MET

Summary: Met/Flt/Flk/Ron/Tie-2 inhibitor

≥25.9 mg/mL
A5017 Motesanib Diphosphate (AMG-706)

Summary: VEGFR/ PDGFR/c-Kit/Ret inhibitor

≥28.45 mg/mL
A2974 Foretinib (GSK1363089)
1 Citation

Summary: VEGF and HGF receptor inhibitor

≥31.65 mg/mL
A2633 Brivanib Alaninate (BMS-582664)

Summary: VEGFR2 inhibitor,ATP-competitive

≥22.05 mg/mL
A1778 Vatalanib (PTK787) 2HCl

Target: VEGFR

Summary: Tyrosine kinase receptor inhibitor

≥21 mg/mL
A5331 TSU-68 (SU6668,Orantinib)

Summary: PDGFR/Flk-1/FGFR1 inhibitor,potent and competitive

insoluble in EtOH; insoluble in H2O; ≥15.5 mg/mL
A5467 Ponatinib (AP24534)
1 Citation

Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src

Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor

≥53.3 mg/mL